Is Amazon an AI Stock?
With the market starting to look skittish on pure-play AI…
Buy
83
BBC Quote, Financials, Valuation and Earnings
Last price:
$38.45
Seasonality move
:
0.58%
Day range:
$36.97 - $38.39
52-week range:
$13.42 - $38.39
Dividend yield:
0.63%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
--
Volume:
48.5K
Avg. volume:
22.8K
1-year change:
41.82%
Market cap:
--
Revenue:
--
EPS (TTM):
--
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
BBC
Virtus LifeSci Biotech Clinical Trials ETF
|
-- | -- | -- | -- | -- |
|
BBP
Virtus LifeSci Biotech Products ETF
|
-- | -- | -- | -- | -- |
|
PFFR
InfraCap REIT Preferred ETF
|
-- | -- | -- | -- | -- |
|
SURI
Simplify Propel Opportunities ETF
|
-- | -- | -- | -- | -- |
|
XHS
State Street SPDR S&P Health Care Services ETF
|
-- | -- | -- | -- | -- |
|
XPH
State Street SPDR S&P Pharmaceuticals ETF
|
-- | -- | -- | -- | -- |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
BBC
Virtus LifeSci Biotech Clinical Trials ETF
|
$38.19 | -- | -- | -- | $0.24 | 0.63% | -- |
|
BBP
Virtus LifeSci Biotech Products ETF
|
$79.36 | -- | -- | -- | $0.00 | 0% | -- |
|
PFFR
InfraCap REIT Preferred ETF
|
$18.03 | -- | -- | -- | $0.12 | 7.99% | -- |
|
SURI
Simplify Propel Opportunities ETF
|
$17.91 | -- | -- | -- | $0.68 | 15.19% | -- |
|
XHS
State Street SPDR S&P Health Care Services ETF
|
$108.20 | -- | -- | -- | $0.07 | 0.24% | -- |
|
XPH
State Street SPDR S&P Pharmaceuticals ETF
|
$54.29 | -- | -- | -- | $0.10 | 0.93% | -- |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
BBC
Virtus LifeSci Biotech Clinical Trials ETF
|
-- | 1.813 | -- | -- |
|
BBP
Virtus LifeSci Biotech Products ETF
|
-- | 0.818 | -- | -- |
|
PFFR
InfraCap REIT Preferred ETF
|
-- | 0.378 | -- | -- |
|
SURI
Simplify Propel Opportunities ETF
|
-- | 1.924 | -- | -- |
|
XHS
State Street SPDR S&P Health Care Services ETF
|
-- | 0.960 | -- | -- |
|
XPH
State Street SPDR S&P Pharmaceuticals ETF
|
-- | 0.588 | -- | -- |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
BBC
Virtus LifeSci Biotech Clinical Trials ETF
|
-- | -- | -- | -- | -- | -- |
|
BBP
Virtus LifeSci Biotech Products ETF
|
-- | -- | -- | -- | -- | -- |
|
PFFR
InfraCap REIT Preferred ETF
|
-- | -- | -- | -- | -- | -- |
|
SURI
Simplify Propel Opportunities ETF
|
-- | -- | -- | -- | -- | -- |
|
XHS
State Street SPDR S&P Health Care Services ETF
|
-- | -- | -- | -- | -- | -- |
|
XPH
State Street SPDR S&P Pharmaceuticals ETF
|
-- | -- | -- | -- | -- | -- |
Virtus LifeSci Biotech Clinical Trials ETF vs. Competitors
-
Which has Higher Returns BBC or BBP?
Virtus LifeSci Biotech Products ETF has a net margin of -- compared to Virtus LifeSci Biotech Clinical Trials ETF's net margin of --. Virtus LifeSci Biotech Clinical Trials ETF's return on equity of -- beat Virtus LifeSci Biotech Products ETF's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital BBCVirtus LifeSci Biotech Clinical Trials ETF-- -- -- BBPVirtus LifeSci Biotech Products ETF-- -- -- -
What do Analysts Say About BBC or BBP?
Virtus LifeSci Biotech Clinical Trials ETF has a consensus price target of --, signalling downside risk potential of --. On the other hand Virtus LifeSci Biotech Products ETF has an analysts' consensus of -- which suggests that it could fall by --. Given that Virtus LifeSci Biotech Clinical Trials ETF has higher upside potential than Virtus LifeSci Biotech Products ETF, analysts believe Virtus LifeSci Biotech Clinical Trials ETF is more attractive than Virtus LifeSci Biotech Products ETF.
Company Buy Ratings Hold Ratings Sell Ratings BBCVirtus LifeSci Biotech Clinical Trials ETF0 0 0 BBPVirtus LifeSci Biotech Products ETF0 0 0 -
Is BBC or BBP More Risky?
Virtus LifeSci Biotech Clinical Trials ETF has a beta of 0.983, which suggesting that the stock is 1.702% less volatile than S&P 500. In comparison Virtus LifeSci Biotech Products ETF has a beta of 0.640, suggesting its less volatile than the S&P 500 by 35.974%.
-
Which is a Better Dividend Stock BBC or BBP?
Virtus LifeSci Biotech Clinical Trials ETF has a quarterly dividend of $0.24 per share corresponding to a yield of 0.63%. Virtus LifeSci Biotech Products ETF offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Virtus LifeSci Biotech Clinical Trials ETF pays -- of its earnings as a dividend. Virtus LifeSci Biotech Products ETF pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios BBC or BBP?
Virtus LifeSci Biotech Clinical Trials ETF quarterly revenues are --, which are smaller than Virtus LifeSci Biotech Products ETF quarterly revenues of --. Virtus LifeSci Biotech Clinical Trials ETF's net income of -- is lower than Virtus LifeSci Biotech Products ETF's net income of --. Notably, Virtus LifeSci Biotech Clinical Trials ETF's price-to-earnings ratio is -- while Virtus LifeSci Biotech Products ETF's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Virtus LifeSci Biotech Clinical Trials ETF is -- versus -- for Virtus LifeSci Biotech Products ETF. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income BBCVirtus LifeSci Biotech Clinical Trials ETF-- -- -- -- BBPVirtus LifeSci Biotech Products ETF-- -- -- --
-
Which has Higher Returns BBC or PFFR?
InfraCap REIT Preferred ETF has a net margin of -- compared to Virtus LifeSci Biotech Clinical Trials ETF's net margin of --. Virtus LifeSci Biotech Clinical Trials ETF's return on equity of -- beat InfraCap REIT Preferred ETF's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital BBCVirtus LifeSci Biotech Clinical Trials ETF-- -- -- PFFRInfraCap REIT Preferred ETF-- -- -- -
What do Analysts Say About BBC or PFFR?
Virtus LifeSci Biotech Clinical Trials ETF has a consensus price target of --, signalling downside risk potential of --. On the other hand InfraCap REIT Preferred ETF has an analysts' consensus of -- which suggests that it could fall by --. Given that Virtus LifeSci Biotech Clinical Trials ETF has higher upside potential than InfraCap REIT Preferred ETF, analysts believe Virtus LifeSci Biotech Clinical Trials ETF is more attractive than InfraCap REIT Preferred ETF.
Company Buy Ratings Hold Ratings Sell Ratings BBCVirtus LifeSci Biotech Clinical Trials ETF0 0 0 PFFRInfraCap REIT Preferred ETF0 0 0 -
Is BBC or PFFR More Risky?
Virtus LifeSci Biotech Clinical Trials ETF has a beta of 0.983, which suggesting that the stock is 1.702% less volatile than S&P 500. In comparison InfraCap REIT Preferred ETF has a beta of 0.717, suggesting its less volatile than the S&P 500 by 28.347%.
-
Which is a Better Dividend Stock BBC or PFFR?
Virtus LifeSci Biotech Clinical Trials ETF has a quarterly dividend of $0.24 per share corresponding to a yield of 0.63%. InfraCap REIT Preferred ETF offers a yield of 7.99% to investors and pays a quarterly dividend of $0.12 per share. Virtus LifeSci Biotech Clinical Trials ETF pays -- of its earnings as a dividend. InfraCap REIT Preferred ETF pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios BBC or PFFR?
Virtus LifeSci Biotech Clinical Trials ETF quarterly revenues are --, which are smaller than InfraCap REIT Preferred ETF quarterly revenues of --. Virtus LifeSci Biotech Clinical Trials ETF's net income of -- is lower than InfraCap REIT Preferred ETF's net income of --. Notably, Virtus LifeSci Biotech Clinical Trials ETF's price-to-earnings ratio is -- while InfraCap REIT Preferred ETF's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Virtus LifeSci Biotech Clinical Trials ETF is -- versus -- for InfraCap REIT Preferred ETF. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income BBCVirtus LifeSci Biotech Clinical Trials ETF-- -- -- -- PFFRInfraCap REIT Preferred ETF-- -- -- --
-
Which has Higher Returns BBC or SURI?
Simplify Propel Opportunities ETF has a net margin of -- compared to Virtus LifeSci Biotech Clinical Trials ETF's net margin of --. Virtus LifeSci Biotech Clinical Trials ETF's return on equity of -- beat Simplify Propel Opportunities ETF's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital BBCVirtus LifeSci Biotech Clinical Trials ETF-- -- -- SURISimplify Propel Opportunities ETF-- -- -- -
What do Analysts Say About BBC or SURI?
Virtus LifeSci Biotech Clinical Trials ETF has a consensus price target of --, signalling downside risk potential of --. On the other hand Simplify Propel Opportunities ETF has an analysts' consensus of -- which suggests that it could fall by --. Given that Virtus LifeSci Biotech Clinical Trials ETF has higher upside potential than Simplify Propel Opportunities ETF, analysts believe Virtus LifeSci Biotech Clinical Trials ETF is more attractive than Simplify Propel Opportunities ETF.
Company Buy Ratings Hold Ratings Sell Ratings BBCVirtus LifeSci Biotech Clinical Trials ETF0 0 0 SURISimplify Propel Opportunities ETF0 0 0 -
Is BBC or SURI More Risky?
Virtus LifeSci Biotech Clinical Trials ETF has a beta of 0.983, which suggesting that the stock is 1.702% less volatile than S&P 500. In comparison Simplify Propel Opportunities ETF has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock BBC or SURI?
Virtus LifeSci Biotech Clinical Trials ETF has a quarterly dividend of $0.24 per share corresponding to a yield of 0.63%. Simplify Propel Opportunities ETF offers a yield of 15.19% to investors and pays a quarterly dividend of $0.68 per share. Virtus LifeSci Biotech Clinical Trials ETF pays -- of its earnings as a dividend. Simplify Propel Opportunities ETF pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios BBC or SURI?
Virtus LifeSci Biotech Clinical Trials ETF quarterly revenues are --, which are smaller than Simplify Propel Opportunities ETF quarterly revenues of --. Virtus LifeSci Biotech Clinical Trials ETF's net income of -- is lower than Simplify Propel Opportunities ETF's net income of --. Notably, Virtus LifeSci Biotech Clinical Trials ETF's price-to-earnings ratio is -- while Simplify Propel Opportunities ETF's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Virtus LifeSci Biotech Clinical Trials ETF is -- versus -- for Simplify Propel Opportunities ETF. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income BBCVirtus LifeSci Biotech Clinical Trials ETF-- -- -- -- SURISimplify Propel Opportunities ETF-- -- -- --
-
Which has Higher Returns BBC or XHS?
State Street SPDR S&P Health Care Services ETF has a net margin of -- compared to Virtus LifeSci Biotech Clinical Trials ETF's net margin of --. Virtus LifeSci Biotech Clinical Trials ETF's return on equity of -- beat State Street SPDR S&P Health Care Services ETF's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital BBCVirtus LifeSci Biotech Clinical Trials ETF-- -- -- XHSState Street SPDR S&P Health Care Services ETF-- -- -- -
What do Analysts Say About BBC or XHS?
Virtus LifeSci Biotech Clinical Trials ETF has a consensus price target of --, signalling downside risk potential of --. On the other hand State Street SPDR S&P Health Care Services ETF has an analysts' consensus of -- which suggests that it could fall by --. Given that Virtus LifeSci Biotech Clinical Trials ETF has higher upside potential than State Street SPDR S&P Health Care Services ETF, analysts believe Virtus LifeSci Biotech Clinical Trials ETF is more attractive than State Street SPDR S&P Health Care Services ETF.
Company Buy Ratings Hold Ratings Sell Ratings BBCVirtus LifeSci Biotech Clinical Trials ETF0 0 0 XHSState Street SPDR S&P Health Care Services ETF0 0 0 -
Is BBC or XHS More Risky?
Virtus LifeSci Biotech Clinical Trials ETF has a beta of 0.983, which suggesting that the stock is 1.702% less volatile than S&P 500. In comparison State Street SPDR S&P Health Care Services ETF has a beta of 1.026, suggesting its more volatile than the S&P 500 by 2.625%.
-
Which is a Better Dividend Stock BBC or XHS?
Virtus LifeSci Biotech Clinical Trials ETF has a quarterly dividend of $0.24 per share corresponding to a yield of 0.63%. State Street SPDR S&P Health Care Services ETF offers a yield of 0.24% to investors and pays a quarterly dividend of $0.07 per share. Virtus LifeSci Biotech Clinical Trials ETF pays -- of its earnings as a dividend. State Street SPDR S&P Health Care Services ETF pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios BBC or XHS?
Virtus LifeSci Biotech Clinical Trials ETF quarterly revenues are --, which are smaller than State Street SPDR S&P Health Care Services ETF quarterly revenues of --. Virtus LifeSci Biotech Clinical Trials ETF's net income of -- is lower than State Street SPDR S&P Health Care Services ETF's net income of --. Notably, Virtus LifeSci Biotech Clinical Trials ETF's price-to-earnings ratio is -- while State Street SPDR S&P Health Care Services ETF's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Virtus LifeSci Biotech Clinical Trials ETF is -- versus -- for State Street SPDR S&P Health Care Services ETF. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income BBCVirtus LifeSci Biotech Clinical Trials ETF-- -- -- -- XHSState Street SPDR S&P Health Care Services ETF-- -- -- --
-
Which has Higher Returns BBC or XPH?
State Street SPDR S&P Pharmaceuticals ETF has a net margin of -- compared to Virtus LifeSci Biotech Clinical Trials ETF's net margin of --. Virtus LifeSci Biotech Clinical Trials ETF's return on equity of -- beat State Street SPDR S&P Pharmaceuticals ETF's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital BBCVirtus LifeSci Biotech Clinical Trials ETF-- -- -- XPHState Street SPDR S&P Pharmaceuticals ETF-- -- -- -
What do Analysts Say About BBC or XPH?
Virtus LifeSci Biotech Clinical Trials ETF has a consensus price target of --, signalling downside risk potential of --. On the other hand State Street SPDR S&P Pharmaceuticals ETF has an analysts' consensus of -- which suggests that it could fall by --. Given that Virtus LifeSci Biotech Clinical Trials ETF has higher upside potential than State Street SPDR S&P Pharmaceuticals ETF, analysts believe Virtus LifeSci Biotech Clinical Trials ETF is more attractive than State Street SPDR S&P Pharmaceuticals ETF.
Company Buy Ratings Hold Ratings Sell Ratings BBCVirtus LifeSci Biotech Clinical Trials ETF0 0 0 XPHState Street SPDR S&P Pharmaceuticals ETF0 0 0 -
Is BBC or XPH More Risky?
Virtus LifeSci Biotech Clinical Trials ETF has a beta of 0.983, which suggesting that the stock is 1.702% less volatile than S&P 500. In comparison State Street SPDR S&P Pharmaceuticals ETF has a beta of 0.657, suggesting its less volatile than the S&P 500 by 34.268%.
-
Which is a Better Dividend Stock BBC or XPH?
Virtus LifeSci Biotech Clinical Trials ETF has a quarterly dividend of $0.24 per share corresponding to a yield of 0.63%. State Street SPDR S&P Pharmaceuticals ETF offers a yield of 0.93% to investors and pays a quarterly dividend of $0.10 per share. Virtus LifeSci Biotech Clinical Trials ETF pays -- of its earnings as a dividend. State Street SPDR S&P Pharmaceuticals ETF pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios BBC or XPH?
Virtus LifeSci Biotech Clinical Trials ETF quarterly revenues are --, which are smaller than State Street SPDR S&P Pharmaceuticals ETF quarterly revenues of --. Virtus LifeSci Biotech Clinical Trials ETF's net income of -- is lower than State Street SPDR S&P Pharmaceuticals ETF's net income of --. Notably, Virtus LifeSci Biotech Clinical Trials ETF's price-to-earnings ratio is -- while State Street SPDR S&P Pharmaceuticals ETF's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Virtus LifeSci Biotech Clinical Trials ETF is -- versus -- for State Street SPDR S&P Pharmaceuticals ETF. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income BBCVirtus LifeSci Biotech Clinical Trials ETF-- -- -- -- XPHState Street SPDR S&P Pharmaceuticals ETF-- -- -- --
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Google Vs NVIDIA Stock: Which Is Best?
Alphabet (NASDAQ:GOOGL) and NVIDIA (NASDAQ:NVIDIA) are two of the market’s…
How High Could NVIDIA Stock Go?
NVIDIA (NASDAQ:NVDA) has been one of the best stocks to…
Stock Ideas
Buy
52
Is NVDA Stock a Buy?
Market Cap: $4.5T
P/E Ratio: 62x
Buy
61
Is AAPL Stock a Buy?
Market Cap: $4.1T
P/E Ratio: 38x
Buy
63
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 40x
Alerts
Buy
54
SMX alert for Dec 5
SMX (Security Matters) Plc [SMX] is up 134.09% over the past day.
Sell
15
HOV alert for Dec 5
Hovnanian Enterprises, Inc. [HOV] is down 0.06% over the past day.
Buy
67
NUTX alert for Dec 5
Nutex Health, Inc. [NUTX] is up 2.97% over the past day.
